We are live on ! Find out more
PCRX icon

Pacira BioSciences
PCRX

185 hedge funds and large institutions have $1.91B invested in Pacira BioSciences in 2017 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 76 increasing their positions, 52 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

81% more call options, than puts

Call options by funds: $26.7M | Put options by funds: $14.8M

46% more repeat investments, than reductions

Existing positions increased: 76 | Existing positions reduced: 52

20% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 30

16% more capital invested

Capital invested by funds: $1.64B → $1.91B (+$268M)

3% more funds holding

Funds holding: 180 → 185 (+5)

5.17% less ownership

Funds ownership: 108.44% → 103.26% (-5.2%)

17% less funds holding in top 10

Funds holding in top 10: 6 → 5 (-1)

Holders
185
Holders Change
+5
Holders Change %
+2.78%
% of All Funds
4.2%
Holding in Top 10
5
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-16.67%
% of All Funds
0.11%
New
36
Increased
76
Reduced
52
Closed
30
Calls
$26.7M
Puts
$14.8M
Net Calls
+$11.9M
Net Calls Change
-$18.5M

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$21.4M
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$15.1M
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$12.4M
4
CCM
Consonance Capital Management
New York
+$8.81M
5
HM
HealthCor Management
New York
+$8.8M

Top Sellers

Rank Fund Capital Flow
1
WRF
Waddell & Reed Financial
Kansas
-$30.6M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$23.1M
3
ACA
Avoro Capital Advisors
New York
-$18.3M
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$15.6M
5
SI
Standard Investments
New York
-$15M
Name Holding Trade Value Shares
Change 		Change in
Stake
ASN
176
Advisory Services Network
Georgia
$8K – – –
SFSIG
177
San Francisco Sentry Investment Group
California
$7K – – –
GT
178
Glenmede Trust
Pennsylvania
$6K +$2.62K +66 +84%
FRA
179
Front Row Advisors
California
$3K +$2.89K +73 New
VFA
180
Valeo Financial Advisors
Indiana
$2K – – –
CIBC Private Wealth Group
181
CIBC Private Wealth Group
Georgia
$1K +$753 +19 New
WRF
182
Waddell & Reed Financial
Kansas
– -$30.6M -815,666 Closed
SI
183
Standard Investments
New York
– -$15M -399,496 Closed
SCM
184
Stonepine Capital Management
Oregon
– -$14.1M -375,200 Closed
SC
185
Samlyn Capital
New York
– -$14M -372,269 Closed
GGHC
186
Gilder Gagnon Howe & Co
New York
– -$8.15M -217,091 Closed
JGC
187
J. Goldman & Co
New York
– -$7.64M -203,400 Closed
CCP
188
Clough Capital Partners
Massachusetts
– -$6.9M -183,800 Closed
GLA
189
Great Lakes Advisors
Illinois
– -$4.58M -122,083 Closed
Susquehanna International Group
190
Susquehanna International Group
Pennsylvania
– -$4.04M -102,025 Closed
NFA
191
Nationwide Fund Advisors
Ohio
– -$3.77M -100,534 Closed
SCM
192
Suffolk Capital Management
New York
– -$1.51M -40,291 Closed
RA
193
RiverPark Advisors
New York
– -$1.23M -32,624 Closed
AI
194
Axiom Investors
Connecticut
– -$627K -16,691 Closed
DCM
195
Dupont Capital Management
Delaware
– -$567K -15,090 Closed
ECM
196
ETrade Capital Management
Virginia
– -$400K -10,664 Closed
SG Americas Securities
197
SG Americas Securities
New York
– -$396K -10,559 Closed
Group One Trading
198
Group One Trading
Illinois
– -$413K -10,423 Closed
HI
199
HBK Investments
Texas
– -$323K -8,600 Closed
Jacobs Levy Equity Management
200
Jacobs Levy Equity Management
New Jersey
– -$273K -7,280 Closed
5 6 7
8
9

PCRX Hedge Fund Activity: Q4 2017 in Review

185 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q4 2017, worth a combined $1.91B — up 16% from $1.64B a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new PCRX positions and 30 closed out — a net gain of 6 holders — while 76 added to existing stakes and 52 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $21.4M. The largest seller was Waddell & Reed Financial, exiting entirely with an estimated $30.6M sold.

  • 185 institutional investors held Pacira BioSciences (PCRX) as of Q4 2017, up from 180 in Q3 2017.
  • Funds reported $1.91B of Pacira BioSciences stock for Q4 2017, up 16% quarter-over-quarter.
  • 36 funds opened new Pacira BioSciences positions in Q4 2017 and 30 closed out, a net change of +6 holders.
  • The largest Pacira BioSciences buyer in Q4 2017 was Millennium Management, an estimated $21.4M added.
  • The largest Pacira BioSciences seller in Q4 2017 was Waddell & Reed Financial, an estimated $30.6M sold.

Based on aggregated 13F filings for Q4 2017.